Updates regarding NextCell’s Clinical Trials with ProTrans

January 24, 2024

NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patients, is progressing well. All 30 patients in the older age group have been recruited and will be treated with ProTrans. In the long-term follow-up studies ProTrans-Obs and ProTrans-Repeat the first diabetes patients have now completed the studies after five years of follow-up.

ProTrans-Young – completed recruitment of the older age group

The study was started in 2021 and is an investigator-initiated clinical study led by Uppsala University in collaboration with Linköping University and Lund University. The goal for this Phase 1/2 study is to evaluate ProTrans for the treatment of paediatric patients newly diagnosed with type 1 diabetes.

The first part of the study was an open Phase 1 safety study with 6 children (ages 7-18) who had recently received their diagnosis. The study progressed well, and therefore the safety committee recommended continuing with Phase 2 of the study, which has been ongoing since the end of 2022. The Phase 2 part of ProTrans-Young is a randomised, placebo-controlled double-blind trial with 30 patients aged 12 – 21 years, and 30 patients aged 7 – 11 years. All patients in the older age group have now been recruited and the last patient in this age group is expected to receive treatment in February of this year. After further safety checks, 30 patients in the age group 7–11 will be recruited. That part of the study is expected to begin in August.

ProTrans-Obs – patients will soon be evaluated

ProTrans-Obs is long-term follow-up of 11 patients who previously participated in ProTrans-2. The first diabetes patients will soon have completed the study after being observed for five years. During the summer, all patients will have completed the study, which can then be evaluated.

Of the patients who completed ProTrans-2, 6 ProTrans-treated and 5 placebo-treated patients accepted an invitation to participate in the follow-up study ProTrans-Obs after completion of the ProTrans-2 study. In this study, the patients' own body insulin production is measured every six months, and a follow-up after three years has already been carried out. The result from this interim analysis shows a statistically significant treatment effect on the body's own insulin production at all analysed times up to three years (p<0.05) as compared to the placebo group.

ProTrans-Repeat – patients will soon be evaluated

ProTrans-Repeat, which started in May 2019, is an open-label follow-up study in which the patients who participated in ProTrans-1 were invited to participate in a second study. The aim is to verify if a second treatment can prolong or maintain a possible effect of ProTrans over a longer period of time, with preserved safety. In this study as well, the first patients have completed the study, and all patients will have completed the trial following their five-year follow-up during the winter.

ProTrans19+SE – first patient in the high dose group treated

In December 2023, the seventh patient with severe viral pneumonia received treatment with ProTrans, and they were also the first patient in the high dose group.

ProTrans is an immunomodulatory cell therapy currently being evaluated for the treatment of patients with type 1 diabetes. However, the mechanism of immune modulation is expected to be applicable in other autoimmune and inflammatory conditions. When COVID-19 patients deteriorate, it is usually because the immune system becomes hyperactive and attacks organs, including the lungs. In this open Phase 1b study, a total of three groups of three patients each will be treated with different doses of ProTrans. Today, 7 out of 9 patients have undergone treatment and only 2 patients in the high-dose group remain to be treated.

At the beginning of 2023, the Swedish Medical Products Agency approved the expansion of the clinical trial to include patients with other forms of virally induced pneumonia. Initially, patients with severe pneumonia caused by SARS-CoV-2 (COVID-19) infection were treated, but now patients with the same clinical symptoms caused by influenza A, respiratory syncytial virus (RSV) and human metapneumovirus (MPV) are also included. The treatment is aimed at patients who are hospitalised and who run a high risk of having to be put on a ventilator. ProTrans is given intravenously to reduce the hyperinflammation in the lungs. The goal of the treatment is to shorten the hospital stay and rehabilitation time, and to save lives.

ProTrans19+CA – terminated prematurely

The study was approved in February 2021. McGill University in Montreal, Canada, sponsored a Phase 2 trial for the treatment of patients with severe pneumonia caused by COVID-19. The aim of the study was to include 48 patients who were randomised to ProTrans (24 patients) or placebo (24 patients). The study was terminated by McGill after 19 patients were treated, due to less patients meeting the criteria for inclusion as the vaccine programme was rolled out.

ProTrans-1 – completed Phase 1 study

The study was started in January 2018 and completed in 2019. An open-label dose-escalation Phase 1 study in 9 patients with type 1 diabetes. ProTrans's safety and impact on the patient's own insulin production were evaluated by measuring insulin production before and one year after treatment. The study showed a) good safety, and b) a dose-dependent effect regarding preservation of the body's own insulin production one year after treatment.

ProTrans-2 – completed Phase 2 study

The study was started in 2019 and completed in 2020. A randomised, double-blinded placebo-controlled Phase 2 study with the main objective of evaluating effectiveness. The study included fifteen newly diagnosed patients with type 1 diabetes. The results showed that patients treated with ProTrans maintained 90% of their body's own insulin production at the time of treatment one year after treatment, compared to 53% in the placebo group. Data from this study have been published in Diabetologia, the official journal of the European Association for the Study of Diabetes (Carlsson et al. 2023 Aug;66(8):1431-1441).

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma


For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se


Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company in Phase 2 trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a Phase 3 trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for COVID-19, in Örebro and in Montreal, Canada. The company is in the process of establishing its own GMP-facility for the production of ProTrans. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.

 

Download attachmentRead full press release on Cision (external link)
2024-02-27
NextCell Pharma’s updated growth strategy
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The new strategic direction means, amongst other things, that Cellaviva will become a wholly owned subsidiary and that the company's GMP facility will have new sources of revenue. The strategic changes will also result in cost savings as a result of staff reduction.
Read moreRead more
2024-02-14
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
Read moreRead more
2024-01-25
NextCell publishes its Interim Report 1 2023/2024
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2024-01-24
Updates regarding NextCell’s Clinical Trials with ProTrans
NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patients, is progressing well. All 30 patients in the older age group have been recruited and will be treated with ProTrans. In the long-term follow-up studies ProTrans-Obs and ProTrans-Repeat the first diabetes patients have now completed the studies after five years of follow-up.
Read moreRead more
2023-12-13
NextCell Pharma has compiled a Q&A section
NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.
Read moreRead more
2023-11-06
Repeated treatment with ProTrans is immunologically safe
NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.
Read moreRead more
2023-10-26
NextCell publishes its Year-End Report 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2023-10-10
NextCell signs an agreement for a new tissue product
NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.
Read moreRead more